Recent advances in platelet engineering for anti-cancer therapies (Open Access)--颗粒学报PARTICUOLOGY

Lv, Y., Wei, W., & Ma, G. (2022). Recent advances in platelet engineering for anti-cancer therapies. Particuology, 64, 2-13. https://doi.org/10.1016/j.partic.2021.09.006

Recent advances in platelet engineering for anti-cancer therapies (Open Access)

Yanlin Lv^a, Wei Wei^{a b}, Guanghui Ma^{a b *}

a State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China
b School of Chemical Engineering, University of Chinese Academy of Sciences, Beijing 100049, China

10.1016/j.partic.2021.09.006

Volume 64, May 2022, Pages 2-13

Received 29 April 2021, Revised 7 September 2021, Accepted 13 September 2021, Available online 27 September 2021, Version of Record 17 December 2021.

E-mail: ghma@ipe.ac.cn

Highlights

• Platelet-based biomimetic strategies have advantages over other anti-cancer therapies.

• Whole platelets and platelet membranes can circumvent host immune responses.

• These strategies provide enhanced tumor cell targeting and drug bioavailability.

• Cargos include apoptotic or photothermal agents or immune checkpoint inhibitors.

• Future directions for platelet-based biomimetic anti-cancer therapies are discussed.

Abstract

Platelets contribute a major role in hemostasis by clumping and coagulation at the site of blood vessel injuries. In light of recent findings of a close relationship between platelets and immunological response, as well as interactions between platelets and cancer cells, novel engineering strategies have emerged for the integration of platelets or platelet membrane (PM) with anti-cancer therapeutics. In this review, we discuss several recent innovations that use platelets or their membranes to circumvent host immune responses and target tumor cells with high specificity to deliver a range of pharmacological, photothermal, or immunologic agents for eradication of recalcitrant tumor cells. More specifically, we compare the relative advantages of using whole platelets versus single or hybrid PM to coat nanoparticle cargoes. These cargoes range from well-established anti-tumor apoptosis-inducing agents, to relatively new photothermal agents that can induce a feedback cascade in which they induce vascular damage to the tumor which recruits more platelet- or membrane-encapsulated agents to induce further damage. We also discuss the use of engineered platelets to produce programmed cell death-inducing platelet derived microparticles. This review provides an overview and future directions for this promising platelet-based biomimetic approach to anti-cancer therapy.

Graphical abstract

Keywords

Engineering platelets; Platelet-mimicking; Drug delivery; Anti-cancer therapy

文章导读